A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 64 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients meeting the Rome III Diagnostic Criteria
Loose (mushy) or watery stools within the last 3 months
Patients with a history of surgical resection of the stomach, small intestine or large intestine
Patients with a history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis ulcerative)
Patients with a history or current diagnosis of colitis ischemic
Patients with a current diagnosis of enteritis infectious
Patients with a current diagnosis of hyperthyroidism or hypothyroidism
Patients who are currently participating in another clinical trial (including a post-marketing clinical study) or those who participated in another clinical trial (including a post-marketing clinical study) within 12 weeks before the study
Patients with a history or current diagnosis of malignant tumor
Patients with a history of abuse of drugs or alcohol within 1 year or those who are currently abusing them